Endocyte, Inc. (NASDAQ:ECYT) saw a significant increase in short interest in October. As of October 13th, there was short interest totalling 2,793,446 shares, an increase of 216.9% from the September 29th total of 881,608 shares. Based on an average daily volume of 14,812,080 shares, the days-to-cover ratio is presently 0.2 days. Currently, 8.9% of the shares of the company are sold short.

Several equities analysts have recently weighed in on the company. Cowen and Company reiterated a “hold” rating on shares of Endocyte in a research report on Monday, October 2nd. Wedbush upgraded Endocyte from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $2.00 to $7.00 in a research report on Tuesday, October 3rd. ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research cut Endocyte from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Shares of Endocyte (NASDAQ ECYT) opened at 4.29 on Thursday. The company’s market cap is $182.65 million. Endocyte has a 1-year low of $1.17 and a 1-year high of $6.55. The company’s 50-day moving average price is $3.16 and its 200 day moving average price is $2.16.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. The business had revenue of $0.01 million during the quarter. During the same period in the previous year, the firm earned ($0.25) EPS. On average, analysts predict that Endocyte will post ($1.06) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Stifel Financial Corp increased its stake in Endocyte by 3.9% in the 1st quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,711 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Endocyte by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares in the last quarter. FMR LLC increased its stake in Endocyte by 0.7% in the 1st quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after buying an additional 24,625 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Endocyte by 34.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Endocyte by 26.7% in the 1st quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 28,110 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Endocyte, Inc. (ECYT) Sees Large Growth in Short Interest” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/26/endocyte-inc-ecyt-sees-large-growth-in-short-interest.html.

About Endocyte

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.